I agree that MSB should unambiguously state if Teva saw the yes/no from the surrogate endpoint analysis, and they should release it to the ASX, not via an email.
I haven't seen any FDA ruling that this data couldn't be released to Teva, especially since it has been part of the trial design from the beginning. Can you find a source?
CHF trial mythbusting, page-3
-
- There are more pages in this discussion • 101 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
0.055(3.77%) |
Mkt cap ! $1.729B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.54 | $1.45 | $6.072M | 4.049M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5951 | $1.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 133644 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |